Approved for To treat KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) after prior systemic therapy. 12.1 Mechanism of Action Avutometinib Avutometinib is a MEK1 inhibitor. Avutometinib induces the formation of inactive RAF/MEK complexes and prevents phosphorylation of MEK1/2 by RAF. RAF and MEK… Side effects, costs, interactions, manufacturer, and generic alternatives sourced from…
Loading full data from Know Your Drugs Institute…